Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2023 | The importance of BCMA, FcRH5 and GPRC5D in multiple myeloma

Paola Neri • 12 May 2023
COMy 2023
Multiple Myeloma

Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, highlights promising targets in multiple myeloma, including BCMA, FcRH5 and GPRC5D, and further comments on the importance of identifying the best sequence when treating patients. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Paola Neri

1:45
Using the available repertoire of bispecific antibodies for treating multiple myeloma
Paola Neri • 17 Feb 2024
1:20
Antigen loss as a key driver of resistance to anti-BCMA T-cell therapies in myeloma
Paola Neri • 17 Feb 2024
Resistance mechanisms mediated by the microenvironment in multiple myeloma
Charlotte Pawlyn et al. • 15 Apr 2023
1:51
Optimizing immunotherapy in myeloma: tumor profiling, mutations & characterizing T-cell fitness
Paola Neri • 12 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals